Results 181 to 190 of about 72,056 (263)

Performance of low-cost noninvasive blood markers of liver cirrhosis in adults with chronic hepatitis B infection with and without comorbid alcohol use in Zambia: A cross-sectional hospital-based study. [PDF]

Medicine (Baltimore)
Mpisa S, Kahere M, Syabbalo E, Kanunga A, Vinikoor M, Sinkala E.   +5 more
europepmc   +1 more source

Risk Stratification of Chronic Kidney Disease in Adults Using Noninvasive Fibrosis Tests Based on the American Diabetes Association Algorithm

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Although the American Diabetes Association (ADA) recently established a diagnostic algorithm for the early detection of liver fibrosis among high‐risk individuals, its implications for chronic kidney disease (CKD) risk stratification remain unclear.
Chan‐Young Jung, Hye Won Lee, Jung Il Lee, Han Ah Lee, Seung Up Kim   +4 more
wiley   +1 more source

COLEC10 and COLEC11 are new serum biomarkers of chronic liver disease. [PDF]

Eur J Med Res
Yang T, Jing Y, Li K, Wang M, Ju S, Zhou Z, Cao X, Zhang M.   +7 more
europepmc   +1 more source

Defining Obesity Under the Lancet Commission Criteria: Metabolic Syndrome–Anchored Body Fat Percentage Thresholds in Korean Adults

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The revised Lancet Commission framework prioritizes excess adiposity over body mass index (BMI) alone for diagnosing obesity, emphasizing population‐specific body fat assessments. However, body fat percentage (BFP) thresholds reflecting adiposity‐defined obesity remain limited, particularly by sex and age in Asian populations.
Han Na Jung, Yun Kyung Cho, Myung Jin Kim, Jung Yoon Moon, Eun Hee Kim, Min Jung Lee, Woo Je Lee, Hong‐Kyu Kim, Chang Hee Jung   +8 more
wiley   +1 more source

Differential Impact of Metabolic Bariatric Surgery Versus Semaglutide on Adverse Hepatic and Extrahepatic Outcomes in Individuals With Metabolic Dysfunction‐Associated Steatotic Liver Disease and Type 2 Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim We compared the impact of metabolic bariatric surgery (MBS) versus semaglutide on clinical outcomes in individuals with metabolic dysfunction‐associated steatotic liver disease (MASLD) and type 2 diabetes (T2D). Methods Patients with MASLD and T2D who had MBS or semaglutide in 2018–2023 were identified (TriNetX database).
Weronika Stupalkowska, Alex E. Henney, David R. Riley, Eric G. Sheu, Uazman Alam, Daniel J. Cuthbertson   +5 more
wiley   +1 more source

Diagnostic challenges of clinically significant portal hypertension in geriatric metabolic dysfunction-associated fatty liver disease: A case report. [PDF]

World J Hepatol
Akbar FN, Darnindro N, Wardhani AA, Choirida SR, Saphira SN, Ismed G, Kshanti IAM, Mustika S, Hendarto H.   +8 more
europepmc   +1 more source

Association of Semaglutide Treatment With Liver Cirrhosis and Hepatocellular Carcinoma in Type 2 Diabetes: A Population‐Based Cohort Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Metabolic dysfunction–associated steatotic liver disease is common among individuals with type 2 diabetes mellitus and substantially increases the risk of liver cirrhosis and hepatocellular carcinoma. Effective therapies that improve metabolic control while preventing advanced liver outcomes are limited.
Assaf Issachar, Talish Razi, Ilya Borochov, Hadar Duskin Bitan, Ronen Arbel   +4 more
wiley   +1 more source

Diabetic ketoacidosis as the initial presentation of hepatogenous diabetes: a first reported case. [PDF]

Endocrinol Diabetes Metab Case Rep
Kutaiba Albuni M, Abbarh S, Ashraf Ibrahem Fathy Hassan N, Sawaf B, Ahmed AI, Hallak Y, Azzawi M.   +6 more
europepmc   +1 more source

ADAM17 and its proteolytic targets in disease pathogenesis

The FEBS Journal, EarlyView.
ADAM17 as a multifunctional sheddase with contrasting roles across inflammatory, metabolic, cardiovascular, and neoplastic diseases. Through regulated activation by iRhom, iTAP/FRMD8, and tetraspanins, ADAM17 cleaves diverse membrane ligands and receptors, thereby promoting inflammation, fibrosis, obesity, insulin resistance, and tumor progression ...
Abdulbasit Amin, Marina Badenes
wiley   +1 more source

Ion channel gene signature for diagnosis and antifibrotic therapy in liver fibrosis. [PDF]

J Transl Med
Li Y, Shen D, Qin F, Chen D, Li J.
europepmc   +1 more source